Duloxetine Capsule, Delayed Release Pellets
Product Images NDC 71610-736

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 71610-736). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 30 mg (71610 0736 42)

Duloxetine Delayed-Release 30 mg capsule label showing product name, strength, quantity of 1800 capsules, NDC 71610-0736-42, storage instructions, manufacturing details by Aphena Pharma Solutions in Cookeville, TN, and batch/expiration placeholders. Label indicates prescription use only.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Chemical Structure (Duloxetine 01)

Chemical structure of Duloxetine Hydrochloride depicted as a molecular diagram showing its aromatic rings and functional groups consistent with the compound's known formula.*

FDA Label Image

Figure 1 (Duloxetine 02)

A line graph comparing the proportion of patients with relapse over time (days) between placebo and Duloxetine delayed-release capsules. The x-axis shows time from randomization to relapse in days, and the y-axis shows the proportion of patients with relapse. Two lines represent treatment groups: a dashed line for placebo and a solid line for Duloxetine delayed-release capsules, indicating lower relapse rates over time with Duloxetine.*

FDA Label Image

Figure 2 (Duloxetine 03)

A Kaplan-Meier curve depicting the proportion of patients with relapse over time from randomization in days, comparing placebo to duloxetine delayed-release capsules treatment groups. The graph shows cumulative relapse rates over approximately 270 days, illustrating differences between placebo and duloxetine groups.*

FDA Label Image

Figure 3 (Duloxetine 04)

A line graph showing the percentage of patients improved based on percent improvement in pain from baseline, comparing Duloxetine hydrochloride dosages (20 mg, 40 mg, 60 mg) to a placebo. The x-axis represents percent improvement in pain, and the y-axis represents the percentage of patients improved. Multiple lines depict results for each dosage level and placebo.*

FDA Label Image

Figure 4 (Duloxetine 05)

A line graph showing the percentage of patients improved relative to the percent improvement in pain from baseline. The graph compares three groups: DUL 60mg BID, DUL 60mg QD, and Placebo, with distinct markers for each group plotted against pain improvement percentages.*

FDA Label Image

Figure 5 (Duloxetine 06)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. The graph compares three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo, tracking pain improvement across increments from 0 to 100%.*

FDA Label Image

Figure 6 (Duloxetine 07)

A line graph depicting the percent improvement in pain from baseline against the percentage of patients with improved pain. The graph compares multiple dose groups of Duloxetine at 120 mg, 60 mg, and 20 mg taken once daily with a placebo group. Each group is represented by separate lines showing trends over the range of pain improvement percentages.*

FDA Label Image

Figure 8 (Duloxetine 08)

A line graph comparing percentage improvement in pain from baseline with placebo and DUL 60/120 mg once daily treatment over time. The x-axis represents percent improvement in pain from baseline, and the y-axis shows the percentage of patients improved. Two lines depict efficacy trends for placebo and DUL 60/120 mg once daily groups.*

FDA Label Image

Figure 9 (Duloxetine 09)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF) between placebo and Duloxetine 60 mg once daily. The x-axis shows percent improvement in pain from baseline, and the y-axis shows percentage of patients improved, with two lines representing placebo and Duloxetine treatment groups.*

FDA Label Image

Figure 10 (Duloxetine 10)

A line graph comparing the percentage of patients improved versus the percent improvement in pain from baseline (BOCF) for Duloxetine Delayed-Release 60/120 mg once daily and placebo. The x-axis represents percent improvement in pain, and the y-axis shows the percentage of patients improved. The graph includes two lines, one for placebo and one for Duloxetine, showing differences in patient improvement across varying pain improvement levels.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.